DRC Ebola Outbreak Spreads to 60 Zones as Vaccinations Begin
The fastest-growing Ebola outbreak in history has expanded to two new health zones in eastern Congo, bringing the total number of affected areas to 60, according to government figures published on Friday. The escalation in North Kivu and Ituri provinces unfolds under severe humanitarian constraints, driven by regional insecurity, population displacement, and a health workers’ strike that continues to impede epidemiological containment.
- The current epidemic has documented 5,794 confirmed cases, including 2,786 deaths, yielding an overall case fatality rate of 48% with significantly higher mortality in newly impacted zones due to delayed response times.
- Congo health authorities initiated targeted vaccinations on August 27, 2026, administering the Ervebo vaccine to frontline workers, while separate clinical trials evaluate candidates for the rare Bundibugyo virus strain.
- The World Health Organization (WHO) warns that the outbreak is on a trajectory to surpass the 2014-2016 West Africa epidemic, with spillover risks threatening neighboring Central African Republic and South Sudan.
Epidemiological Spread Across North Kivu and Ituri Provinces
According to data released by Congo’s Ministry of Health, the newly affected zones are Biena and Manguredjipa in North Kivu province. The case fatality rate in these specific sectors exceeds the broader epidemic average of 48%. This disparity stems directly from delayed clinical response efforts and logistical barriers. The northeastern Ituri province remains the primary epicenter, housing more than 83% of all recorded cases. The World Health Organization notes that the vast majority of infections and fatalities continue to occur outside monitored contact tracing networks, spreading directly within local communities.
The transmission dynamics are exacerbated by intense population movements and security challenges.
Vaccination Protocols and Clinical Trial Realities
On August 27, 2026, Congo’s Health Minister Roger Kamba administered the first doses of the Ervebo vaccine to healthcare workers in Kisangani. While Ervebo demonstrated high efficacy in past outbreaks driven by the Zaire species, the current epidemic is caused by the rarer Bundibugyo virus strain. According to updates from the World Health Organization, there are currently no approved vaccines or specific therapeutics licensed for the Bundibugyo virus, prompting ongoing clinical trials to identify viable countermeasures.
Regional Spillover Risks and International Response
Although neighboring Uganda declared itself free of Ebola last month, the WHO reported that cross-border transmission risks remain elevated. WHO expert Marie Roseline Belizaire stated that the Central African Republic is currently the nation at the highest risk of viral spillover, followed closely by South Sudan as the eastern Congo outbreak expands toward frontier regions.
Containment measures implemented by local authorities—ranging from restrictions on public gatherings to sanitary checkpoints at transit hubs—aim to disrupt transmission chains.
*Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.*